重庆华森制药股份有限公司 2024 年度独立董事述职报告 尊敬的各位股东及股东代表： 本人杜守颖作为重庆华森制药股份有限公司（以下简称"公司"或"华森制 药"）的独立董事，2024 年度严格按照证监会、交易所等相关法规及要求，积极 出席董事会及股东大会会议，认真审阅董事会、股东大会各项会议议案，并对相 关事项发表意见，充分发挥了独立董事及各专门委员会委员的作用，切实维护了 公司和全体股东的利益。现将本人 2024 年履职情况作如下汇报： 一、基本情况及独立性说明 （一）独立董事基本情况 杜守颖，女，1960 年出生，中国国籍，无境外居留权。北京中医药大学临床 中药专业博士学位，教授。曾任常州千红药业股份有限公司、上海景峰制药有限 公司、浙江新光药业股份有限公司、北京星昊医药股份有限公司、广东众生药业 股份有限公司、湖南景峰医药股份有限公司、重庆太极实业（集团）股份有限公 司、西藏奇正藏药股份有限公司、湖北省宏源药业科技股份有限公司独立董事； 现任湖南方盛制药股份有限公司、片仔癀制药股份有限公司、重庆华森制药股份 有限公司独立董事，北京北中资产管理有限公司董事；社会学术兼职主要有中国 中医药促进会药物经济学专业 ...

重庆华森制药股份有限公司 2024 年度独立董事述职报告 尊敬的各位股东及股东代表： 大家好！本人作为重庆华森制药股份有限公司（以下简称"公司"或"华森 制药"）的独立董事，2024 年度严格按照证监会、交易所等相关法规及要求，勤 勉尽责，忠实履行独立董事职责，积极参加会议，现将本人 2024 年履职情况作 报告如下： 一、基本情况 （一）独立董事基本情况 3.本人没有为公司、公司的控股股东、实际控制人或附属企业提供财务、法 律、咨询及保荐等服务、没有从公司及其主要股东或有利害关系的机构和人员取 得额外的、未予披露的其他利益。 综上所述，本人不存在影响独立性的情况，符合《上市公司独立董事管理办 第 1 页 共 9 页 法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》及公司《独立董事工作细则》等相关规定中独立性的要求。 二、年度履职情况 （一）出席股东大会及董事会情况 作为公司独立董事，本人拥有专业资质及能力，在从事的专业领域积累了丰 富的经验。本人个人工作履历、专业背景以及任职情况如下： 李嘉明，男，1965 年出生，中国国籍，无境外居留权。中共党员。重庆大学 管理学博士、会计学 ...

Dividend Policy - The company plans to distribute a cash dividend of 0.50 CNY per 10 shares (including tax) to all shareholders[3]. - The cash dividend policy stipulates that at least 10% of the distributable profit must be allocated as cash dividends annually, provided there are no significant capital expenditures[191]. - For the 2024 interim dividend, the company intends to distribute RMB 0.35 per 10 shares, amounting to approximately RMB 14,615,870.99, which is about 31% of the net profit attributable to shareholders for the first half of 2024[195]. - The total cash dividend for 2024 is expected to be approximately RMB 35.5 million, accounting for about 46% of the net profit attributable to shareholders of the listed company for that year[198]. - The profit distribution plan requires approval from the board and shareholders, with independent directors having a role in the decision-making process[193]. - The company’s cash dividend distribution must be completed within two months after the shareholders' meeting approval[193]. - The company has committed to maintaining transparent communication with shareholders, especially minority shareholders, regarding dividend policies and decisions[194]. Financial Performance - The company's revenue for 2024 reached ¥774,819,866.89, representing a 12.04% increase compared to ¥691,542,793.48 in 2023[18]. - Net profit attributable to shareholders increased by 134.66% to ¥76,730,225.12 in 2024 from ¥32,699,150.22 in 2023[18]. - The net profit after deducting non-recurring gains and losses rose by 146.94% to ¥51,210,295.72 in 2024, up from ¥20,738,116.85 in 2023[18]. - Basic earnings per share increased by 134.61% to ¥0.1837 in 2024, compared to ¥0.0783 in 2023[18]. - The total assets of the company at the end of 2024 were ¥1,917,549,589.00, a 3.57% increase from ¥1,851,453,889.14 at the end of 2023[18]. - The net assets attributable to shareholders increased by 2.60% to ¥1,659,998,278.38 at the end of 2024, compared to ¥1,617,921,007.43 at the end of 2023[18]. - Cash flow from operating activities decreased by 26.25% to ¥161,766,809.02 in 2024 from ¥219,341,327.29 in 2023[18]. Research and Development - The company invested 73.03 million yuan in R&D, accounting for 9.43% of operating revenue, with R&D expenses representing 7.63% of operating revenue[41]. - The company is focusing on the development of innovative drugs in oncology, tumor immunity, and metabolic diseases, with a pipeline covering various solid tumors[36]. - The company has established a PROTAC technology platform and is advancing 1 PROTAC small molecule innovative drug project[36]. - The company has submitted 4 innovative drug compound invention patent applications, with 1 granted, and a total of 17 applications filed, including 6 PCT patents[36]. - The company is advancing four innovative drug research pipelines targeting various cancers, with 17 patent applications filed for innovative drug compounds, including 4 authorized patents[44]. - The company aims to achieve a rolling target of developing at least six new generic or traditional Chinese medicine products each year during the 14th Five-Year Plan period[123]. Market Expansion - The company is actively pursuing new strategies in product development and market expansion to enhance its competitive position[9]. - The company is expanding its market presence through the establishment of a new GMP production base as part of its fundraising projects[9]. - The company has established a subsidiary in the United States, Pharscin US Inc., which is part of its international expansion strategy[9]. - The company is actively expanding its business from domestic to international markets, adapting to new technologies and demands[30]. - The company has successfully registered its key traditional Chinese medicine product, Ganqi Bingmei Tablets, in Singapore, marking its first overseas product registration[42]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by 2025[150]. Corporate Governance - The company has a total of 9 directors, including 3 independent directors, which constitutes one-third of the board members[153]. - The company has established a complete and independent financial department, ensuring no interference from the controlling shareholder in financial activities[160]. - The company has a performance evaluation and incentive mechanism for directors, supervisors, and senior management, ensuring transparency and fairness[156]. - The company maintains complete independence from its controlling shareholder in business, personnel, assets, institutions, and financial operations[159]. - The company has a dedicated internal audit department that supervises daily operations and major transactions[157]. Challenges and Risks - The company has faced challenges due to price reductions in pharmaceutical products and increased market competition, impacting its revenue and profit margins[28]. - The company acknowledges the high risks associated with innovative drug development, including long timelines and significant investment requirements[137]. - The company faces policy risks due to stringent regulations in the pharmaceutical industry, which could impact product market access and profitability[136]. - The company recognizes management risks associated with its expanding scale and is focused on enhancing internal control and management capabilities[140]. Product Development - The company has launched 11 new health consumer products and obtained 3 new drug registration certificates during the reporting period[33]. - The company is developing a First-In-Class small molecule innovative drug targeting colorectal and pancreatic cancers, with a short-term goal to achieve IND application by 2025 and long-term goal to secure market approval in Greater China by 2026[90]. - The company is working on multiple generic drugs, including C3602 Capsules and C4002 Tablets, with plans for registration submissions and market launches to boost revenue[91]. - The company has established a GMP production base, significantly increasing production capacity and generating cash flow from CMO and CDMO services[57]. Employee and Management - The total number of employees at the end of the reporting period is 1,384, including 1,296 at the parent company and 88 at major subsidiaries[186]. - The company has a total of 582 sales personnel, 320 technical staff, and 310 production workers, indicating a strong focus on sales and technical capabilities[186]. - The management team includes experienced professionals with diverse backgrounds in pharmaceuticals and engineering, ensuring strong leadership[170]. - The company has established a comprehensive compensation system, including salary management, education subsidies, and annual salary adjustments[188]. Strategic Goals - The company plans to introduce at least three new drug varieties to the market annually over the next five years, alongside continuous launches of special medical foods and health consumer products[124]. - The company aims to establish an international division to enhance global business development, focusing on Southeast Asia markets like Singapore and Malaysia[133]. - The company has initiated a strategic acquisition plan, aiming to acquire two smaller firms to enhance its product portfolio[146]. - The company plans to accelerate the launch of in-development projects and enhance its product pipeline to strengthen its market competitiveness[143].

Financial Performance - The company's revenue for Q1 2025 was ¥238,944,153.42, representing a 4.62% increase compared to ¥228,392,771.39 in the same period last year[5]. - Net profit attributable to shareholders was ¥40,355,212.38, showing a slight increase of 0.01% from ¥40,351,252.07 year-on-year[5]. - Total revenue for the current period reached ¥238,944,153.42, an increase of 4.8% compared to ¥228,392,771.39 in the previous period[23]. - Net profit for the current period was ¥40,355,212.38, slightly up from ¥40,351,252.07 in the previous period, indicating a stable performance[24]. - The company's total assets increased to ¥1,953,562,392.47 from ¥1,917,549,589.00, representing a growth of 1.9%[22]. - The total liabilities decreased to ¥253,065,305.37 from ¥257,551,310.62, a reduction of 1.9%[22]. - The retained earnings rose to ¥721,986,844.70 from ¥681,631,632.32, marking an increase of 5.9%[22]. - Basic and diluted earnings per share remained stable at ¥0.0966 for both periods[24]. Cash Flow - The net cash flow from operating activities increased significantly by 146.83%, reaching ¥21,860,943.05, primarily due to an increase in the settlement of acceptance bills[5]. - Operating cash flow for the current period is ¥21,860,943.05, a significant increase of 147.5% compared to ¥8,856,696.04 in the previous period[25]. - Total cash inflow from operating activities is ¥191,675,253.51, up from ¥169,841,410.14, reflecting a growth of 12.3%[25]. - Cash outflow from operating activities increased to ¥169,814,310.46 from ¥160,984,714.10, representing a rise of 5.1%[25]. - The company reported a cash outflow of ¥28,800.00 from financing activities, an improvement from a cash outflow of ¥100,200.00 in the previous period[26]. - The impact of exchange rate changes on cash and cash equivalents was a negative ¥136,374.95, contrasting with a positive impact of ¥7,308.33 previously[26]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,953,562,392.47, up 1.88% from ¥1,917,549,589.00 at the end of the previous year[5]. - The total current assets at the end of the period amounted to ¥1,091,355,563.01, an increase from ¥1,031,344,511.28 at the beginning of the period[20]. - The company has a long-term equity investment of ¥14,188,853.36, down from ¥15,414,034.45 at the beginning of the period[20]. - The company's inventory decreased to ¥127,823,788.51 from ¥140,125,411.63 at the beginning of the period[20]. - The company reported a decrease in contract liabilities from ¥8,688,989.46 to ¥4,550,742.76, a decline of 47.7%[22]. Market Performance - Sales of the key product, Ganqi Bingmei Tablets, experienced a decline due to reduced market demand, while other key traditional Chinese medicines showed growth, with Liuwu Anshen Capsules increasing by 32.10% and Tongxiening Granules by 80.24%[9]. - The overall growth of national drug collection varieties was 28.71%, indicating strong market access and execution capabilities[9]. Other Financial Metrics - The company's weighted average return on equity decreased to 2.40% from 2.46% year-on-year[5]. - Other income decreased by 34.98% to ¥2,348,546.56, primarily due to a reduction in government subsidies received[11]. - The company reported a credit impairment loss of ¥2,014,007.51, a decrease of 30.76% compared to the previous year, attributed to enhanced collection efforts[12]. - Research and development expenses were ¥12,304,890.58, slightly down from ¥12,644,702.28, indicating a focus on cost management[23]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,712[15]. - The largest shareholder, Chengdu Local Construction Machinery Engineering Co., Ltd., holds 42.04% of the shares[15]. - The total number of preferred shareholders at the end of the reporting period is not applicable[18]. Investment Activities - The net cash flow from investing activities decreased significantly by 4961.47% to -¥181,171,345.21, mainly due to an increase in the purchase of financial products[16]. - Total cash outflow for investment activities was ¥302,374,756.73, significantly higher than ¥3,579,423.53 in the previous period[25]. - The company received ¥120,000,000.00 from investment recoveries during the current period, with no such inflow reported in the previous period[25].

医药板块持续走高 众生药业等多股涨停 智通财经4月22日电，午后医药板块持续走高，创新药方向继续领涨，众生药业、华森制药、富士莱涨 停，百利天恒、诺诚健华、新诺威、百济神州创历史新高，复旦张江、上海谊众、信立泰、热景生物等 涨幅靠前。消息面上，4月25日至4月30日，美国癌症研究协会（AACR）年会将在芝加哥召开。作为全 球规模最大的癌症研究会议之一，AACR年会一直是癌症领域最新研究成果的重要展示平台。 ...

关于公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日收到重庆市药品监督 管理局颁发的《药品生产许可证》（许可证编号：渝20150018），本次变更主要涉 及核减受托生产（仅限注册申报使用）、新增受托生产和产品通过药品生产质量管 理规范符合性检查。具体情况如下： 一、变更内容 1.核减受托生产（仅限于注册申报）：委托方是重庆希韦医药科技有限公司， 受托品种是二甲双胍恩格列净片（I）、二甲双胍恩格列净片（VI），生产场地是 重庆市荣昌区昌州街道板桥路 143 号 503 车间片剂生产线，受托有效期至 2025 年 11 月 9 日； 2.新增受托生产：委托方是重庆希韦医药科技有限公司，受托品种是二甲双胍 恩格列净片（I）（国药准字：H20249711）、二甲双胍恩格列净片（VI）（国药准 字 H20249712），生产场地是重庆市荣昌区昌州街道板桥路 143 号 503 车间片剂生 产线，受托有效期至 2025 年 11 月 9 日； 3.重庆市荣昌区昌州街道板桥路 143 号 503 ...

Group 1 - The core point of the announcement is that Chongqing Huason Pharmaceutical Co., Ltd. has received the Supplementary Application Approval Notice for Orlistat Capsules from the National Medical Products Administration, indicating a change in the marketing authorization holder [1][2] - Orlistat Capsules are currently the only approved oral treatment for obesity or overweight patients (BMI ≥ 24) in China, primarily working by reducing fat absorption from food [2][3] - The company has transitioned to self-branding "Quchang" for the sales operation of Orlistat Capsules after reaching an agreement with its partner to change the marketing authorization back to the partner while still allowing the company to produce the product [2][3] Group 2 - The company has also received re-registration approval notices for eight other drugs, ensuring their normal production and sales, which include Cang'erzi Nasal Inhalation Capsules and Spirulina Capsules among others [6][12] - Cang'erzi Nasal Inhalation Capsules are recognized as a classic medication for nasal diseases and are included in the national medical insurance list, indicating a strong market position [9] - Spirulina Capsules have shown significant effects in enhancing immunity and regulating blood lipids, supported by multiple clinical studies, which may enhance the company's product portfolio and market competitiveness [10][11]

证券代码：002907 证券简称：华森制药 公告编号：2025-017 重庆华森制药股份有限公司 关于公司获得奥利司他胶囊药品补充申请批准通知 书的公告 生 产 企 业：名称：重庆华森制药股份有限公司 地址：重庆市荣昌区昌州街道板桥路 143 号 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）近日收到国家药品监督管 理局（以下简称"国家药监局"）核准签发的关于公司产品奥利司他胶囊的《药 品补充申请批准通知书》，将变更奥利司他胶囊的上市许可持有人等内容。现就 相关情况公告如下： 一、药品基本信息 | 药 | 品 | 名 | 称：奥利司他胶囊 | | --- | --- | --- | --- | | | 英文名 | / | 拉 丁 名：Orlistat Capsules | | 剂 | | | 型：胶囊剂 | | 注 | 册 | 分 | 类：化学药品 | | 规 | | | 格：0.12g | | 受 | | 理 | 号：CYHB2500485 | | 通 | 知 | 书 编 | 号：2025B01424 | | 原 ...

证券代码：002907 证券简称：华森制药 公告编号：2025-016 | 药 | 品 | | 通 | 用 | | 名 称：苍耳子鼻炎胶囊 | | --- | --- | --- | --- | --- | --- | --- | | 受 | | | 理 | | | 号：CYZZ2418271 渝 | | 通 | | 知 | 书 | | 编 | 号：2025R023290 | | 剂 | | | | | | 型：胶囊剂 | | 规 | | | | | | 格：每粒装 0.4g | | 注 | | 册 | | | 分 | 类：中药：无 | | 药 | 品 | 注 | 册 | 标 | 准 | 号：WS3-B-2701-97-4 编 | | 药 | 品 | | 批 | 准 | | 文 号：国药准字 Z20033142 | | 药 | | 品 | 有 | | 效 | 期：18 个月 | | | | 药 品 批 准 文 号 | | | | 有 效 期：至 2030 年 03 月 27 日 | | 审 | | 批 | | | 结 | 论：经审查，本品符合《药品注册管理办法》的有关 规定，同意再注册。 | （二）螺旋藻胶囊 ...

证券代码：002907 证券简称：华森制药 公告编号：2025-015 | 产 | 品 | 名 | 称 ：DULIANG RUANJIAONANG | （都梁软胶囊） | | --- | --- | --- | --- | --- | | 产 | 品 | 类 | 别 ：中成药 | | | 品 | 牌 | 名 | 称 ：华森 | | | 剂 | | | 型 ：胶囊剂 | | | 生 | | 产 | 商 ：重庆华森制药股份有限公司 | | | 注 | 册 | 编 | 号 ：129809 | | 二、药品的其他情况 都梁软胶囊为公司重点中成药，是中药 1.1 类创新药，进入国家医保目录 （医保流水号：653）、2020 年版《中国药典》，是国家重大新药创制项目成果， 并荣获中国专利奖和省级科技进步奖。都梁软胶囊由川芎、白芷两味药食同源的 药材组成，具有祛风散寒、疏通升散、活血化瘀止痛的功效。《都梁软胶囊预防 治疗慢性每日头痛（含慢性偏头痛、慢性紧张型头痛）有效性和安全性的多中心、 随机、双盲、安慰剂对照研究》等多项 RCT 及 Meta 分析研究显示，都梁软胶囊 通过镇痛、抗炎及扩张血管、降低血液黏度、改善微循环的 ...